Literature DB >> 34907581

Validation of self-reported medication use applying untargeted mass spectrometry-based metabolomics techniques in the Rhineland study.

Nersi Alaeddin1, Julia C Stingl2, Monique M B Breteler1,3, Folgerdiena M de Vries1.   

Abstract

AIMS: To assess the validity of self-reported continuous medication use with drug metabolites measured in plasma by using untargeted mass spectrometric techniques.
METHODS: In a population-based cohort in Bonn, Germany, we compared interview-based, self-reported medication intake with drug-specific metabolites measured in plasma (based on participants who completed their study visits between March 2016 and February 2020). Analyses were done stratified by sex and age (<65 years vs ≥65 years). Cohen's kappa (κ) statistics with 95% confidence intervals (CI) were calculated.
RESULTS: A total of 13 drugs used to treat hypertension, gout, diabetes, epilepsy and depression were analysed in a sample of 4386 individuals (mean age 55 years, 56.1% women). Eleven drugs showed almost perfect agreement (κ > 0.8), whereas sitagliptin and hydrochlorothiazide showed substantial (κ = 0.8, 95% CI 0.71-0.90) and moderate agreement (κ = 0.61, 95% CI 0.56-0.66), respectively. Frequency of use allowed sex- and age-stratified analyses for eight and nine drugs, respectively. For five drugs, concordance tended to be higher for women than for men. For most drugs, concordance was higher among individuals aged ≥65 years than among individuals aged <65 years, but these age-related differences were not statistically significant.
CONCLUSION: High concordance rates between self-reported drug use and metabolites measured in plasma suggest that self-reported drug use is reliable and accurate for assessing drug use.
© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Entities:  

Keywords:  mass spectrometry; metabolomics; molecular epidemiology; pharmacoepidemiology; self-reported data; validity

Mesh:

Year:  2021        PMID: 34907581     DOI: 10.1111/bcp.15175

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  1 in total

1.  Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19.

Authors:  Nicolas Hoertel; Marina Sánchez-Rico; Johannes Kornhuber; Erich Gulbins; Angela M Reiersen; Eric J Lenze; Bradley A Fritz; Farid Jalali; Edward J Mills; Céline Cougoule; Alexander Carpinteiro; Christiane Mühle; Katrin Anne Becker; David R Boulware; Carlos Blanco; Jesús M Alvarado; Nathalie Strub-Wourgaft; Cédric Lemogne; Frédéric Limosin
Journal:  J Clin Med       Date:  2022-10-05       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.